Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease

Ashraf Mikhail, Christopher Brown, Jennifer Ann Williams, Vinod Mathrani, Rajesh Shrivastava, Jonathan Evans, Hayleigh Isaac, Sunil Bhandari, Ashraf Mikhail, Christopher Brown, Jennifer Ann Williams, Vinod Mathrani, Rajesh Shrivastava, Jonathan Evans, Hayleigh Isaac, Sunil Bhandari

Abstract

Anaemia is a commonly diagnosed complication among patients suffering with chronic kidney disease. If left untreated, it may affect patient quality of life. There are several causes for anaemia in this patient population. As the kidney function deteriorates, together with medications and dietary restrictions, patients may develop iron deficiency, resulting in reduction of iron supply to the bone marrow (which is the body organ responsible for the production of different blood elements). Chronic kidney disease patients may not be able to utilise their own body's iron stores effectively and hence, many patients, particularly those receiving haemodialysis, may require additional iron treatment, usually provided by infusion.With further weakening of kidney function, patients with chronic kidney disease may need additional treatment with a substance called erythropoietin which drives the bone marrow to produce its own blood. This substance, which is naturally produced by the kidneys, becomes relatively deficient in patients with chronic kidney disease. Any patients will eventually require treatment with erythropoietin or similar products that are given by injection.Over the last few years, several iron and erythropoietin products have been licensed for treating anaemia in chronic kidney disease patients. In addition, several publications discussed the benefits of each treatment and possible risks associated with long term treatment. The current guidelines provide advice to health care professionals on how to screen chronic kidney disease patients for anaemia, which patients to investigate for other causes of anaemia, when and how to treat patients with different medications, how to ensure safe prescribing of treatment and how to diagnose and manage complications associated with anaemia and the drugs used for its treatment.

Conflict of interest statement

Competing interests

All authors made declarations of interest in line with the policy in the Renal Association Clinical Practice Guidelines Development Manual. Further details can be obtained on request from the Renal Association.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926. doi: 10.1136/.
    1. Uhlig K, MacLeod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from kidney disease: improving global outcomes (KDIGO) Kidney Int. 2006;70:2058–2065. doi: 10.1038/sj.ki.5001875.
    1. National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Guideline on anaemia management in chronic kidney disease. 2015. National Institute for Clinical Excellence. Available on . Accessed 15 June 2017.
    1. National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Guideline on chronic kidney disease in adults: assessment and management 2014. National Institute for Clinical Excellence. Available on . Accessed 15 June 2017.
    1. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. NephrolDialTransplant. 2004;19(Suppl 2):ii1–i47.
    1. Locatelli F, Bárány P, Covic A, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–59.
    1. KDOQI National Kidney Foundation clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(5 Suppl 3):S16–S85.
    1. KDIGO Clinical practice guideline for Anaemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335. doi: 10.1038/kisup.2012.37.
    1. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin α on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148–156. doi: 10.1097/01.ASN.0000102471.89084.8B.
    1. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of haemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005;46:799–811. doi: 10.1053/j.ajkd.2005.08.007.
    1. Oski FA, Brugnara C, Nathan DG. Nathan and Oski's Haematology of infancy and childhood. 6th. Philadelphia: Saunders; 2003. A diagnostic approach to the anaemic patient; pp. 409–418.
    1. World Health Organisation . Iron deficiency anaemia, assessment, prevention and control: a guide for programme managers. 2001.
    1. Beall CM, Goldstein MC. Haemoglobin concentration of pastoral nomads permanently resident at 4,850-5,450 meters in Tibet. Am J Phys Anthropol. 1987;73:433–438. doi: 10.1002/ajpa.1330730404.
    1. Cheng CK, Chan J, Cembrowski GS, van Assendelft OW. Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race. Lab Hematol. 2004;10:42–53. doi: 10.1532/LH96.04010.
    1. de Lusignan S, Chan T, Stevens P, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22:234–241. doi: 10.1093/fampra/cmi026.
    1. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anaemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anaemia. Blood. 2004;104:2263–2268. doi: 10.1182/blood-2004-05-1812.
    1. Ishimura E, Nishizawa Y, Okuno S, et al. Diabetes mellitus increases the severity of anaemia in non-dialyzed patients with renal failure. J Nephrol. 1998;11:83–86.
    1. Bosman DR, Winkler AS, Marsden JT, et al. Anaemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24:495–499. doi: 10.2337/diacare.24.3.495.
    1. Thomas MC, MacIsaac RJ, Tsalamandris C, et al. Unrecognized anaemia in patients with diabetes: a cross-sectional survey. Diabetes Care. 2003;26:1164–1169. doi: 10.2337/diacare.26.4.1164.
    1. Thomas MC, MacIsaac RJ, Tsalamandris C, et al. The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol Dial Transplant. 2004;19:1792–1797. doi: 10.1093/ndt/gfh248.
    1. El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anaemia with diabetes mellitus in moderate kidney insufficiency: the kidney early evaluation program. Kidney Int. 2005;67:1483–1488. doi: 10.1111/j.1523-1755.2005.00226.x.
    1. Erslev AJ, Besarab A. The rate and control of baseline red cell production in haematologically stable patients with uraemia. J Lab Clin Med. 1995;126(3):283–286.
    1. Naets JP, Garcia JF, Tousaaint C, et al. Radioimmunoassay of erythropoietin in chronic uraemia or nephric patients. Scand J Haematol. 1986;37:390–394. doi: 10.1111/j.1600-0609.1986.tb02626.x.
    1. Ross RP, McCrea JB, Besarab A. Erythropoietin response to blood loss in haemodialysis patients in blunted but preserved. ASAIO J. 1994;40:M880–M885. doi: 10.1097/00002480-199407000-00122.
    1. Movilli E, Pertica N, Camerini C, et al. Pre dialysis versus post dialysis haematocrit evaluation during erythropoietin therapy. Am J Kidney Dis. 2002;39:850–853. doi: 10.1053/ajkd.2002.32007.
    1. Bellizzi V, Minutolo R, Terracciano V, et al. Influence of the cyclic variation of hydration status on haemoglobin levels in haemodialysis patients. Am J Kidney Dis. 2002;40:549–555. doi: 10.1053/ajkd.2002.34913.
    1. Fishbane S, Lynn RI. The efficacy of iron dextran for the treatment of iron deficiency in haemodialysis patients. Clin Nephrol. 1995;44:238–240.
    1. Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis. 1999;34:508–513. doi: 10.1016/S0272-6386(99)70079-X.
    1. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Luft FC, et al. Diagnosis of iron deficiency anaemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis. 1995;26:292–299. doi: 10.1016/0272-6386(95)90649-5.
    1. KDOQI guidelines on anaemia management: . Accessed 15 June 2017.
    1. Coban E, Timuragaoglu A, Meric M. Iron deficiency anaemia in the elderly: prevalence and endoscopic evaluation of the gastrointestinal tract in outpatients. Acta Haematol. 2003;110:25–28. doi: 10.1159/000072410.
    1. Ioannou GN, Rockey DC, Bryson CL, et al. Iron deficiency and gastrointestinal malignancy: a population-based cohort study. Am J Med. 2002;113:276–280. doi: 10.1016/S0002-9343(02)01214-7.
    1. Ioannou GN, Spector J, Scott K, et al. Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anaemia. Am J Med. 2002;113:281–287. doi: 10.1016/S0002-9343(02)01226-3.
    1. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in haemodialysis patients. J Am Soc Nephrol. 2000;11:530–538.
    1. Besarab A, Dalton CL. Maintaining higher TSATs and other iron indices is beneficial in management of anaemic haemodialysis patients. Nephrol Nurs J. 2001;28:429–434.
    1. Coladonato JA, Frankenfield DL, Reddan DN, et al. Trends in anaemia management among US haemodialysis patients. J Am Soc Nephrol. 2002;13:1288–95.
    1. Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance haemodialysis patients. Am J Kidney Dis. 2003;42:761–773. doi: 10.1016/S0272-6386(03)00915-6.
    1. McClellan WM, Frankenfield DL, Wish JB, et al. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult haemodialysis patients: results from the 1998 end-stage renal disease Core indicators project. Am J Kidney Dis. 2001;37:E36.
    1. Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in haemodialysis patients. Am J Kidney Dis. 2001;38:109–117. doi: 10.1053/ajkd.2001.25203.
    1. UK Renal Registry. UK Renal Registry Report: The Seventeenth Annual Report. 2014. . Accessed 15 June 2017.
    1. Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in haemodialysis patients. Kidney Int. 2001;60(6):2406–2411. doi: 10.1046/j.1523-1755.2001.00077.x.
    1. Fishbane S, Galgano C, Langley RC, Jr, et al. Reticulocyte haemoglobin content in the evaluation of iron status of haemodialysis patients. Kidney Int. 1997;52(1):217–222. doi: 10.1038/ki.1997.323.
    1. Kaneko Y, Miyazaki S, Hirasawa Y, et al. Transferrin saturation versus reticulocyte haemoglobin content for iron deficiency in Japanese haemodialysis patients. Kidney Int. 2003;63:1086–1109. doi: 10.1046/j.1523-1755.2003.00826.x.
    1. Bhandari S, Turney JH, Brownjohn AM, et al. Reticulocyte indices in patients with end stage renal disease on haemodialysis. J Nephrol. 1998;11(2):78–82.
    1. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16(7):1416–1423. doi: 10.1093/ndt/16.7.1416.
    1. Chen YC, Hung SC, Tarng DC. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in haemodialysis patients. Am J Kidney Dis. 2006;47(6):1036–1044. doi: 10.1053/j.ajkd.2006.02.180.
    1. National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for Anaemia in chronic kidney disease. Section III. Clinical practice recommendations for anaemia in chronic kidney disease in children. Am J Kidney Dis. 2006;47:S86–108.
    1. Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anaemic patients with non-dialysis dependent CKD. Kidney Int. 2005;68:2846–2856. doi: 10.1111/j.1523-1755.2005.00758.x.
    1. Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in pre-dialysis chronic renal failure patients. Ren Fail. 2002;24:307–313. doi: 10.1081/JDI-120005364.
    1. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anaemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234–238. doi: 10.1016/S0272-6386(96)90546-6.
    1. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16:967–974. doi: 10.1093/ndt/16.5.967.
    1. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anaemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55–c62. doi: 10.1159/000085049.
    1. Ahsan N. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial. Adv Perit Dial. 2000;16:80–84.
    1. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88(4):905–914. doi: 10.1038/ki.2015.163.
    1. Macdougall IC, Bock AH, Carrera F, et al. For the FIND-CKD study investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29:2075–2084. doi: 10.1093/ndt/gfu201.
    1. Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31:646–655. doi: 10.1093/ndt/gfv293.
    1. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in haemodialysis patients. Am J Kidney Dis. 1999;34:21–28. doi: 10.1016/S0272-6386(99)70103-4.
    1. Macdougall IC, Chandler G, Elston O, et al. Beneficial effects of adopting an aggressive intravenous iron policy in a haemodialysis unit. Am J Kidney Dis. 1999;34:S40–S46. doi: 10.1053/ajkd.1999.v34.aajkd0344b0040.
    1. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41–46. doi: 10.1016/0272-6386(95)90151-5.
    1. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694–1699. doi: 10.1038/ki.1996.487.
    1. Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;0:1–13.
    1. Macdougall IC, Bircher AJ, Eckardt KU, et al. Conference participants. Iron management in chronic kidney disease: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2016;89(1):28–39. doi: 10.1016/j.kint.2015.10.002.
    1. Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65(3):1091–1098. doi: 10.1111/j.1523-1755.2004.00480.x.
    1. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term haemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89(1):87–93. doi: 10.1111/j.1600-0609.2012.01783.x.
    1. Rostoker G, Griuncelli M, Loridon C, et al. Haemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012;125(10):991–999. doi: 10.1016/j.amjmed.2012.01.015.
    1. Coyne DW, Kapoian T, Suki W, et al. DRIVE study group. Ferric gluconate is highly efficacious in anaemic haemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to IV iron with elevated Ferritin (DRIVE) study. J Am Soc Nephrol. 2007;18:975–984. doi: 10.1681/ASN.2006091034.
    1. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anaemia correction in incident haemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16(7):2180–2189. doi: 10.1681/ASN.2004121039.
    1. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving haemodialysis and epoetin. N Engl J Med. 1998;339(9):584–590. doi: 10.1056/NEJM199808273390903.
    1. Singh AK, Szczech L, Tang KL, et al. Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098. doi: 10.1056/NEJMoa065485.
    1. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of haemoglobin level in patients with chronic kidney disease and anaemia. N Engl J Med. 2006;355(20):2071–2084. doi: 10.1056/NEJMoa062276.
    1. (PROCRIT ®: Clinical Study Report PR00–06-014 (CHOIR) Synopsis, 12 September 2006; available at: . Accessed 15 June 2017.
    1. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved haemoglobin outcomes. Kidney Int. 2008;74(6):791–798. doi: 10.1038/ki.2008.295.
    1. Szczech LA, Barnhart HX, Sapp S, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anaemia treatment. Kidney Int. 2010;77(3):239–246. doi: 10.1038/ki.2009.415.
    1. KDOQI clinical practice guideline and clinical practice recommendations for anaemia in chronic kidney disease, 2007 update of haemoglobin target. Am J Kidney Dis. 2007;50(3):471–530.
    1. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–2032. doi: 10.1056/NEJMoa0907845.
    1. Macdougall IC, Tomson CR, Steenkamp M, et al. Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK renal registry data incorporating 30,040 patient-years of follow-up. Nephrol Dial Transplant. 2010;25(3):914–919. doi: 10.1093/ndt/gfp550.
    1. Brookhart MA, Schneeweiss S, Avorn J, et al. Comparative mortality risk of anaemia management practices in incident haemodialysis patients. JAMA. 2010;303(9):857–864. doi: 10.1001/jama.2010.206.
    1. Locatelli F, Aljama P, Canaud B, et al. Anaemia working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;25(9):2846–2850. doi: 10.1093/ndt/gfq336.
    1. UK Renal Registry. UK Renal Registry Report: The fourteenth Annual Report. 2011. . Accessed 15 June 2017.
    1. Medicines and Healthcare products Regulatory Agency: Recombinant human erythropoietins: new advice for prescribing. . Accessed 15 June 2017.
    1. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anaemic patients with end-stage renal disease. Results of a phase III multicentre clinical trial. Ann Intern Med. 1989;111(12):992–1000. doi: 10.7326/0003-4819-111-12-992.
    1. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anaemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989;321(3):158–163. doi: 10.1056/NEJM198907203210305.
    1. Locatelli F, Olivares J, Walker R. Et al; European/ Australian NESP 980202 study group. Novel erythropoiesis stimulating protein for treatment of anaemia in chronic renal insufficiency. Kidney Int. 2001;60(2):741–747. doi: 10.1046/j.1523-1755.2001.060002741.x.
    1. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving haemodialysis. Department of Veterans Affairs Cooperative Study Group on erythropoietin in Haemodialysis patients. N Engl J Med. 1998;339(9):578–583. doi: 10.1056/NEJM199808273390902.
    1. Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin α at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo) Nephrol Dial Transplant. 2003;18:362–369. doi: 10.1093/ndt/18.2.362.
    1. Vanrenterghem Y, Bárány P, Mann JF, et al. European/ Australian NESP 970200 study group. Randomized trial of darbepoetin alfa for treatment of renal anaemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002;62(6):2167–2175. doi: 10.1046/j.1523-1755.2002.00657.x.
    1. Spinowitz B, Coyne DW, Lok CE, et al. RUBRA study investigators: C.E.R.A. Maintains stable control of haemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008;28(2):280–289. doi: 10.1159/000111115.
    1. Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by haemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007;50(6):989–1000. doi: 10.1053/j.ajkd.2007.08.013.
    1. Tolman C, Richardson D, Bartlett C, et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol. 2005;16:1463–1470. doi: 10.1681/ASN.2004080688.
    1. Jadoul M, Vanrenterghem Y, Foret M, et al. Darbepoetin α administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004;19:898–903. doi: 10.1093/ndt/gfh021.
    1. Fishbane S, Berns JS. Haemoglobin cycling in haemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–1343. doi: 10.1111/j.1523-1755.2005.00532.x.
    1. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anaemia in haemodialysis patients. Am J Kidney Dis. 2002;40(1):110–8.5. doi: 10.1053/ajkd.2002.33919.
    1. FDA presentation at Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting, 18 October 2010. . Accessed 15 June 2017.
    1. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153(1):23–33. doi: 10.7326/0003-4819-153-1-201007060-00252.
    1. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for haemoglobin-survival paradox in haemodialysis. Am J Kidney Dis. 2008;52:727–736. doi: 10.1053/j.ajkd.2008.05.029.
    1. MHRA Drug Safety Update Recombinant human erythropoietins: treating anaemia in cancer. r. Accessed 15 June 2017.
    1. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Haematology and the American Society of Clinical Oncology practice guideline update committee. American Society of Haematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045–4059. doi: 10.1182/blood-2010-08-300541.
    1. National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Erythropoiesis-stimulating agents Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer ha anaemia in people with cancer having chemotherapy. 2014. National Institute for Clinical Excellence. . Accessed 15 June 2017.
    1. NKF-K/DOQI clinical practice guidelines for Anaemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001;37:S182–238.
    1. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in haemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol. 2008;3:1691–1701. doi: 10.2215/CJN.01070308.
    1. Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:77–83. doi: 10.2215/CJN.04190510.
    1. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671–1676. doi: 10.3324/haematol.2014.111492.
    1. Novey HS, Pahl M, Haydik I, et al. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994;72:224–228.
    1. Agarwal R, Vasavada N, Sachs NG, et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279–2289. doi: 10.1111/j.1523-1755.2004.00648.x.
    1. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980;243:1726–1731. doi: 10.1001/jama.1980.03300430028018.
    1. Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in haemodialysis patients. Am J Kidney Dis. 1996;28:529–534. doi: 10.1016/S0272-6386(96)90463-1.
    1. Michael B, Coyne DW, Fishbane S, et al. Ferrlecit publication committee. Sodium ferric gluconate complex in haemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61(5):1830–1839. doi: 10.1046/j.1523-1755.2002.00314.x.
    1. MHRA Drug Safety Update (2013) Intravenous iron and serious hypersensitivity reactions: strengthened recommendations. . Accessed 15 June 2017.
    1. Weiss G, Meusburger E, Radacher G, et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int. 2003;64:572–578. doi: 10.1046/j.1523-1755.2003.00099.x.
    1. Nairz M, Schroll A, Sonnweber T, Weiss G, et al. The struggle for iron - a metal at the host-pathogen interface. Cell Microbiol. 2010;12:1691–1702. doi: 10.1111/j.1462-5822.2010.01529.x.
    1. Ganz T. Iron in innate immunity: starve the invaders. Curr Opin Immunol. 2009;21:63–67. doi: 10.1016/j.coi.2009.01.011.
    1. Fritsche G, Nairz M, Werner ER, et al. Nramp1-functionality increases iNOS expression via repression of IL-10 formation. Eur J Immunol. 2008;38:3060–3067. doi: 10.1002/eji.200838449.
    1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–1023. doi: 10.1056/NEJMra041809.
    1. Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant. 2014;29:809–822. doi: 10.1093/ndt/gft524.
    1. Ishida JH, Johansen KL. Iron and infection in haemodialysis patients. Semin Dial. 2014;27(1):26–36. doi: 10.1111/sdi.12168.
    1. Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus maintenance iron supplementation in haemodialysis patients. J Am Soc Nephrol. 2013;24(7):1151–1158. doi: 10.1681/ASN.2012121164.
    1. Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014;86(4):845–854. doi: 10.1038/ki.2014.114.
    1. Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in haemodialysis patients. J Am Soc Nephrol. 2002;13(3):734–744.
    1. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among haemodialysis patients. J Am Soc Nephrol. 2004;15(6):1623–1632. doi: 10.1097/.
    1. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in haemodialysis patients. J Am Soc Nephrol. 2005;16(10):3070–3080. doi: 10.1681/ASN.2005040423.
    1. Kshirsagar AV, Freburger JK, Ellis AR, et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in haemodialysis patients. PLoS One. 2013;8(11):e78930. doi: 10.1371/journal.pone.0078930.
    1. Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL: a multicentre prospective study of risk factors for bacteraemia in chronic haemodialysis patients. J Am Soc Nephrol. 1998;9:869–876.
    1. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteraemia in chronic haemodialysis patients. Clin Nephrol. 2002;57(6):457–461. doi: 10.5414/CNP57457.
    1. Horl WH, Jacobs C, Macdougall IC, et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant. 2000;15(Suppl 4):43–50. doi: 10.1093/ndt/15.suppl_4.43.
    1. Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant. 1998;13(Suppl 2):3–8. doi: 10.1093/ndt/13.suppl_2.3.
    1. Jacobs C, Horl WH, Macdougall IC, et al. European best practice guidelines 5: target haemoglobin. Nephrol Dial Transplant. 2000;15(Suppl 4):15–19. doi: 10.1093/ndt/15.suppl_4.15.
    1. Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol. 1975;30:411. doi: 10.1111/j.1365-2141.1975.tb01855.x.
    1. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67:2346. doi: 10.1111/j.1523-1755.2005.00340.x.
    1. Cournoyer D, Toffelmire EB, Wells GA, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol. 2004;15:2728. doi: 10.1097/01.ASN.0000140219.28618.9F.
    1. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469. doi: 10.1056/NEJMoa011931.
    1. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol. 2004;15:398. doi: 10.1097/01.ASN.0000107561.59698.42.
    1. Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant. 2003;18:865. doi: 10.1093/ndt/gfg182.
    1. Weber G, Gross J, Kromminga A, et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002;13:2381. doi: 10.1097/01.ASN.0000027031.79843.6C.
    1. Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol. 2008;3:193. doi: 10.2215/CJN.02440607.
    1. Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004;73:389. doi: 10.1111/j.1600-0609.2004.00348.x.
    1. Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re- treatment: multiple options. Nephrol Dial Transplant. 2005;20(Suppl 4):iv23. doi: 10.1093/ndt/gfh1090.
    1. Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the research on adverse drug events and reports (RADAR) project. Blood. 2005;106:3343. doi: 10.1182/blood-2005-02-0508.
    1. Verhelst D, Rossert J, Casadevall N, et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004;363(9423):1768–1771. doi: 10.1016/S0140-6736(04)16302-2.
    1. . Accessed 15 June 2017.
    1. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292(13):1555–1562. doi: 10.1001/jama.292.13.1555.
    1. Zarychanski R, Houston DS. Anaemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ. 2008;179(4):333–337. doi: 10.1503/cmaj.071131.
    1. Soosay A, O'Neill D, Counihan A, et al. Causes of sensitisation in patients awaiting renal transplantation in Ireland. Ir Med J. 2003;96(4):109–112.
    1. House AA, Pham B, Pagé DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant. 1998;13(7):1763–1769. doi: 10.1093/ndt/13.7.1763.
    1. Popovsky MA, Ransil BJ. Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. Immunohematology. 1996;12(1):1–3.
    1. Manchester Kidney Transplant, NWKTA Audit Project; 2003.
    1. National Institute for Clinical Excellence. Blood transfusion . Accessed 15 June 2017.
    1. SaBTO (2015) HEV SCT Clinician Letter draft v0.3i. . Accessed 15 June 2017.
    1. Yorgin PD, Scandling JD, Belson A, et al. Late post-transplant anaemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant. 2002;2(5):429–435. doi: 10.1034/j.1600-6143.2002.20506.x.
    1. Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of post-transplant anaemia in paediatric and young adult renal transplant recipients. Am J Kidney Dis. 2002;40(6):1306–1318. doi: 10.1053/ajkd.2002.36910.
    1. Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anaemia in renal transplant recipients: a European survey. Am J Transplant. 2003;3(7):835–845. doi: 10.1034/j.1600-6143.2003.00133.x.
    1. Abraham KA, Little MA, Dorman AM, et al. Haemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int. 2000;13(6):443–447. doi: 10.1111/j.1432-2277.2000.tb01023.x.
    1. Epstein M, Landsberg D. Cyclosporine-induced thrombotic microangiopathy resulting in renal allograft loss and its successful reuse: a report of two cases. Am J Kidney Dis. 1991;17(3):346–348. doi: 10.1016/S0272-6386(12)80486-0.
    1. Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis. 2000;36(4):844–850. doi: 10.1053/ajkd.2000.17690.
    1. Trimarchi HM, Truong LD, Brennan S, et al. Report of two cases and review of the literature. Transplantation. 1999;67(4):539–544. doi: 10.1097/00007890-199902270-00009.
    1. Zarifian A, Meleg-Smith S, O'donovan R, et al. Cyclosporine associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55(6):2457–2466. doi: 10.1046/j.1523-1755.1999.00492.x.
    1. Dussol B, Brunet P, Vacher-Coponat H, et al. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy. Nephrol Dial Transplant. 1994;9(8):1191–1193. doi: 10.1093/ndt/9.8.1191.
    1. Morris-Stiff G, Evans M, Baboolal K, et al. Haemolytic uraemic syndrome associated with OKT3. Transpl Int. 1996;9(5):522–523. doi: 10.1111/j.1432-2277.1996.tb01001.x.
    1. MacDonald AS, RAPAMUNE Global Study Group A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271–280. doi: 10.1097/00007890-200101270-00019.
    1. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc. 2003;35(3 Suppl):25S–34S. doi: 10.1016/S0041-1345(03)00351-8.
    1. Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant. 2004;4(12):2001–2006. doi: 10.1111/j.1600-6143.2004.00612.x.
    1. Crew RJ, Radhakrishnan J, Cohen DJ, et al. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant. 2005;20(1):203–209. doi: 10.1093/ndt/gfh334.
    1. Winkelmayer WC, Kewalramani R, Rutstein M, et al. Pharmacoepidemiology of anaemia in kidney transplant recipients. J Am Soc Nephrol. 2004;15(5):1347–1352. doi: 10.1097/01.ASN.0000125551.59739.2E.
    1. Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis. 2001;38(3):510–517. doi: 10.1053/ajkd.2001.26839.
    1. Naito M, Kawashima A, Akiba T, Takanashi M, et al. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic haemodialysis patients. Am J Nephrol. 2003;23(5):287–293. doi: 10.1159/000072705.
    1. So BJ, Chae KM, Lee KK, et al. Pure red cell aplasia due to parvovirus B19 infection in a renal transplant patient: a case report. Transplant Proc. 2000;32(7):1954–1956. doi: 10.1016/S0041-1345(00)01509-8.
    1. Vales-Albertos LJ, García-Cárdenas M, Chávez-Becerra S, et al. Pure red cell aplasia associated with parvovirus B19 infection in renal transplantation: the first case report in Mexico. Transplantation. 2005;79(6):739. doi: 10.1097/01.TP.0000149339.25047.F4.
    1. Debska-Slizień A, Chamienia A, Król E, et al. Haemolytic anaemia after renal transplantation: analysis of case reports. Transplant Proc. 2003;35(6):2233–2237. doi: 10.1016/S0041-1345(03)00774-7.
    1. Peces R, Díaz Corte C, Navascués RA. Haemolytic anaemia caused by graft-versus host reaction in ABO-non identical renal transplants from blood group O donors. Nefrologia. 2001;21(4):395–401.
    1. Li FK, Chan TM, Lai KN. Alloimmune haemolysis after renal transplantation. Am J Nephrol. 2000;20(6):473–475. doi: 10.1159/000046202.
    1. Moulin B, Ollier J, George F. Serum erythropoietin and reticulocyte maturity index after renal transplantation: a prospective longitudinal study. Nephron. 1995;69(3):259–266. doi: 10.1159/000188467.
    1. Schmidt R, Kupin W, Dumler F, et al. Influence of the pre-transplant hematocrit level on early graft function in primary cadaveric renal transplantation. Transplantation. 1993;55(5):1034–1040. doi: 10.1097/00007890-199305000-00016.
    1. Vasquez EM, Pollack R. Effect of pre-transplant erythropoietin therapy on renal allograft outcome. Transplantation. 1996;62(7):1026–1028. doi: 10.1097/00007890-199610150-00024.
    1. Paganini EP, Braun WE, Latham D, et al. Renal transplantation: results in haemodialysis patients previously treated with recombinant human erythropoietin. ASAIO Trans. 1989;35(3):535–538. doi: 10.1097/00002480-198907000-00117.
    1. Lee DB. Interrelationship between erythropoietin and erythropoiesis: insights from renal transplantation. Am J Kidney Dis. 1991;18(4 Suppl 1):54–56.
    1. Van Loo A, Vanholder R, Bernaert P, et al. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nephrol Dial Transplant. 1996;11(9):1815–1821. doi: 10.1093/ndt/11.9.1815.
    1. Van Biesen W, Vanholder R, Veys N, et al. Efficacy of erythropoietin administration in the treatment of anaemia immediately after renal transplantation. Transplantation. 2005;79(3):367–368. doi: 10.1097/01.TP.0000150370.51700.99.
    1. Jindal KK, Hirsch DJ, Belitsky P, et al. Low-dose subcutaneous erythropoietin corrects the anaemia of renal transplant failure. Nephrol Dial Transplant. 1992;7(2):143–146. doi: 10.1093/oxfordjournals.ndt.a092085.
    1. Muirhead N, Cattran DC, Zaltzman J, et al. Safety and efficacy of recombinant human erythropoietin in correcting the anaemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol. 1994;5(5):1216–1222.
    1. Becker BN, Becker YT, Leverson GE, Heisey DM. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant. 2002;17(9):1667–1673. doi: 10.1093/ndt/17.9.1667.
    1. Choukroun G, Kamar N, Dussol B, et al. For the CAPRIT study investigators. Correction of post kidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23(2):360–368. doi: 10.1681/ASN.2011060546.
    1. Traindl O, Barnas U, Franz M, et al. Recombinant human erythropoietin in renal transplant recipients with renal anaemia. Clin Transpl. 1994;8(1):45–48.
    1. Yoshimura N, Oka T, Ohmori Y, Aikawa I. Effects of recombinant human erythropoietin on the anaemia of renal transplant recipients with chronic rejection. Transplantation. 1989;48(3):527–529. doi: 10.1097/00007890-198909000-00038.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir